CTOs on the Move

Bridge Medicines

www.bridgemedicines.com

 
Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Bridge Medicines raised $10M on 11/13/2020

Similar Companies

Alphora Research Inc

Alphora Research Inc is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PriorAuthNow

PriorAuthNow`s powerful, secure software works with your EHR system and connects directly with all insurance carriers, making it the fastest, most economical way to submit, monitor and complete prior authorizations.

Advitech

Advitech is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IMIDomics

IMIDomics is a biotechnology company focused on Patient-Centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d`Hebron Institute of Research, to establish a deeper understanding of IMID diseases. By doing so, IMIDomics has identified previously unrecognized targets, six of which have been selected for development. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need.